|
|
|
| Efficacy and Safety of Thoracic Endovascular Aortic Repair combined with Drug in Patients with Stanford B Type Aortic Dissection |
| GUAN Jun, ZENG Qian, DENG Chao |
| Haikou People’s Hospital, Hainan Haikou 570208, China |
|
|
|
|
Abstract Objective: To study the efficacy and safety of thoracic endovascular aortic repair (TEVAR) combined with drug and absolute drug therapy in patients with Stanford B type aortic dissection (Stanford B type AD). Methods: The clinical data of 86 patients with Stanford B type AD admitted to our hospital from2010.01 to 2015.01 were retrospectively analyzed. According to the treatment Methods, they were divided into combined group (TEVAR+drug therapy, n=56) and drug group (pure drug therapy, n=30). The treatment effects were observed in the two groups. Results: The success rate of surgical technique was 100% in combined group. There were no significant differences in the various complications during hospitalization between the two groups (P>0.05). There was no significant difference infatality rate during hospitalization (P>0.05). At 12~48 months of follow-up after operation, there were no significant differences in the fatality rate, major complications and maximum diameter of true lumen between the two groups (P>0.05), and the thrombosis formation rate and thrombus absorption rate in combined group were significantly higher than those in drug group (P>0.05), and the maximum diameter of false lumen was significantly less than that in drug group (P<0.05). The median survival time in drug group and combined group both were 48 months, and the Log Rank test showed there was no significant difference in survival rate between the two groups (χ2=0.50, P>0.05). Conclusion: TEVAR combined with drug therapy can effectively improve the thrombosis formation rate and thrombus absorption rate in patients with Stanford B type aortic dissection, and reduce the maximum diameter of false lumen. However, it has more postoperative complications and can not effectively extend the survival time of patients.
|
|
|
|
|
|
[1] 陈昭然,黄毕,樊晓寒,等.合并高血压的急性主动脉夹层患者的临床特征及预后[J].中华心血管病杂志,2016,44(3):220~225.
[2] 樊纪丹,杨岷,易晨龙,等.Stanford B型主动脉夹层动脉瘤临床治疗分析[J].检验医学与临床,2017,14(2):69~71.
[3] 薛金熔,李滨,刘永民,等.急性主动脉夹层合并下肢缺血的外科治疗效果[J].中华医学杂志,2017,97(14):1093~1095.
[4] 郭义山,丛超,杨宁,等.主动脉夹层发病机制的研究进展[J].医学综述,2017,23(12):2339~2343.
[5] 彭文星,赵宏磊,乔环宇,等.急性主动脉夹层的药物辅助治疗[J].中华胸心血管外科杂志,2018,34(4):254~256.
[6] 王江云,陈勇,李彦豪,等.腔内修复或药物治疗稳定型B型主动脉夹层[J].介入放射学杂志,2017,26(3):266~269. |
| [1] |
. [J]. 河北医学, 2017, 23(9): 1573-1576. |
|
|
|
|
2019, Vol. 25 
